A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6
医学
基底细胞
癌
肿瘤科
皮肤病科
内科学
作者
Brett Hughes,Alexander Guminski,Samantha Bowyer,Michael R. Migden,Chrysalyne D. Schmults,Nikhil I. Khushalani,Anne Lynn S. Chang,Jean‐Jacques Grob,Karl D. Lewis,George Ansstas,Fiona Day,Rahul Ladwa,B. Stein,Eva Muñoz‐Couselo,Friedegund Meier,Axel Hauschild,Dirk Schadendorf,Nicole Basset‐Séguin,Badri Modi,S. Dalac‐Rat